Anika Therapeutics Stock Forecast, Price & News

Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

Is Anika Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Anika Therapeutics stock.
View analyst ratings for Anika Therapeutics or view top-rated stocks.

How has Anika Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Anika Therapeutics' stock was trading at $36.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ANIK stock has increased by 7.9% and is now trading at $39.25.
View which stocks have been most impacted by COVID-19.

Are investors shorting Anika Therapeutics?

Anika Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 756,300 shares, a drop of 29.3% from the October 31st total of 1,070,000 shares. Based on an average daily trading volume, of 72,200 shares, the short-interest ratio is currently 10.5 days. Approximately 5.3% of the company's stock are short sold.
View Anika Therapeutics' Short Interest.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Anika Therapeutics.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.26. The biotechnology company had revenue of $39.54 million for the quarter, compared to analyst estimates of $36.45 million. Anika Therapeutics had a positive trailing twelve-month return on equity of 1.63% and a negative net margin of 3.96%. During the same period in the prior year, the firm earned ($0.45) earnings per share.
View Anika Therapeutics' earnings history.

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics updated its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $142.20 million-$144.81 million, compared to the consensus revenue estimate of $147.52 million.

What price target have analysts set for ANIK?

3 equities research analysts have issued 12-month target prices for Anika Therapeutics' stock. Their forecasts range from $46.00 to $55.00. On average, they expect Anika Therapeutics' stock price to reach $49.67 in the next year. This suggests a possible upside of 26.5% from the stock's current price.
View analysts' price targets for Anika Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the following people:

• Cheryl Renee Blanchard, President, Chief Executive Officer & Director
• Michael L. Levitz, Chief Financial Officer, Treasurer & EVP (LinkedIn Profile)
• Mira Leiwant, VP-Quality, Regulatory & Clinical Affairs
• Steven W. Ek, Vice President-Research & Development
• David Colleran, Secretary, Executive VP & General Counsel

Who are some of Anika Therapeutics' key competitors?

Some companies that are related to Anika Therapeutics include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), ICU Medical (ICUI), STAAR Surgical (STAA), Neogen (NEOG), Merit Medical Systems (MMSI), Haemonetics (HAE), Atrion (ATRI), Cerus (CERS), Meridian Bioscience (VIVO), OraSure Technologies (OSUR) and Antares Pharma (ATRS).
View all of ANIK's competitors.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.03%), Kayne Anderson Rudnick Investment Management LLC (10.08%), Dimensional Fund Advisors LP (5.97%), Renaissance Technologies LLC (4.88%), Morgan Stanley (3.92%) and Janus Henderson Group PLC (3.21%). Company insiders that own Anika Therapeutics stock include James Loerop, John B Henneman III, Michael L Levitz, Michael L Levitz, Michael L Levitz and Raymond J Land.
View institutional ownership trends for Anika Therapeutics.

Which institutional investors are selling Anika Therapeutics stock?

ANIK stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, BlackRock Inc., Two Sigma Advisers LP, Citadel Advisors LLC, Citigroup Inc., Russell Investments Group Ltd., GSA Capital Partners LLP, and Arrowstreet Capital Limited Partnership.
View insider buying and selling activity for Anika Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Anika Therapeutics stock?

ANIK stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Trigran Investments Inc., Assenagon Asset Management S.A., Capital Management Corp VA, SG Americas Securities LLC, Jump Financial LLC, UBS Group AG, and Marshall Wace LLP. Company insiders that have bought Anika Therapeutics stock in the last two years include John B Henneman III, and Michael L Levitz.
View insider buying and selling activity for Anika Therapeutics or or view top insider-buying stocks.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $39.25.

How much money does Anika Therapeutics make?

Anika Therapeutics has a market capitalization of $566.65 million and generates $130.46 million in revenue each year. The biotechnology company earns $-23.98 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Anika Therapeutics have?

Anika Therapeutics employs 277 workers across the globe.

When was Anika Therapeutics founded?

Anika Therapeutics was founded in 1992.

What is Anika Therapeutics' official website?

The official website for Anika Therapeutics is www.anikatherapeutics.com.

Where are Anika Therapeutics' headquarters?

Anika Therapeutics is headquartered at 32 WIGGINS AVENUE, BEDFORD MA, 01730.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at (781) 457-9000, via email at [email protected], or via fax at 781-305-9720.